The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis

a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative

on behalf of the NAIMS Cooperative

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Over the past few years, MRI has become an indispensable tool for diagnosing multiple sclerosis (MS). However, the current MRI criteria for MS diagnosis have imperfect sensitivity and specificity. The central vein sign (CVS) has recently been proposed as a novel MRI biomarker to improve the accuracy and speed of MS diagnosis. Evidence indicates that the presence of the CVS in individual lesions can accurately differentiate MS from other diseases that mimic this condition. However, the predictive value of the CVS for the development of clinical MS in patients with suspected demyelinating disease is still unknown. Moreover, the lack of standardization for the definition and imaging of the CVS currently limits its clinical implementation and validation. On the basis of a thorough review of the existing literature on the CVS and the consensus opinion of the members of the North American Imaging in Multiple Sclerosis (NAIMS) Cooperative, this article provides statements and recommendations aimed at helping radiologists and neurologists to better understand, refine, standardize and evaluate the CVS in the diagnosis of MS.

Original languageEnglish (US)
JournalNature Reviews Neurology
DOIs
StateAccepted/In press - Nov 11 2016

Fingerprint

Multiple Sclerosis
Veins
Demyelinating Diseases
Biomarkers
Sensitivity and Specificity

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience

Cite this

@article{5974ef1df16d48ad9379a79d20b74293,
title = "The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative",
abstract = "Over the past few years, MRI has become an indispensable tool for diagnosing multiple sclerosis (MS). However, the current MRI criteria for MS diagnosis have imperfect sensitivity and specificity. The central vein sign (CVS) has recently been proposed as a novel MRI biomarker to improve the accuracy and speed of MS diagnosis. Evidence indicates that the presence of the CVS in individual lesions can accurately differentiate MS from other diseases that mimic this condition. However, the predictive value of the CVS for the development of clinical MS in patients with suspected demyelinating disease is still unknown. Moreover, the lack of standardization for the definition and imaging of the CVS currently limits its clinical implementation and validation. On the basis of a thorough review of the existing literature on the CVS and the consensus opinion of the members of the North American Imaging in Multiple Sclerosis (NAIMS) Cooperative, this article provides statements and recommendations aimed at helping radiologists and neurologists to better understand, refine, standardize and evaluate the CVS in the diagnosis of MS.",
author = "{on behalf of the NAIMS Cooperative} and Pascal Sati and Jiwon Oh and Constable, {R. Todd} and Nikos Evangelou and Guttmann, {Charles R G} and Henry, {Roland G.} and Klawiter, {Eric C.} and Caterina Mainero and Luca Massacesi and Henry McFarland and Flavia Nelson and Daniel Ontaneda and Alexander Rauscher and William Rooney and Samaraweera, {Amal P R} and Shinohara, {Russell T.} and Sobel, {Raymond A.} and Solomon, {Andrew J.} and Treaba, {Constantina A.} and Jens Wuerfel and Robert Zivadinov and Sicotte, {Nancy L.} and Daniel Pelletier and Reich, {Daniel S.}",
year = "2016",
month = "11",
day = "11",
doi = "10.1038/nrneurol.2016.166",
language = "English (US)",
journal = "Nature Reviews Neurology",
issn = "1759-4758",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis

T2 - a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative

AU - on behalf of the NAIMS Cooperative

AU - Sati, Pascal

AU - Oh, Jiwon

AU - Constable, R. Todd

AU - Evangelou, Nikos

AU - Guttmann, Charles R G

AU - Henry, Roland G.

AU - Klawiter, Eric C.

AU - Mainero, Caterina

AU - Massacesi, Luca

AU - McFarland, Henry

AU - Nelson, Flavia

AU - Ontaneda, Daniel

AU - Rauscher, Alexander

AU - Rooney, William

AU - Samaraweera, Amal P R

AU - Shinohara, Russell T.

AU - Sobel, Raymond A.

AU - Solomon, Andrew J.

AU - Treaba, Constantina A.

AU - Wuerfel, Jens

AU - Zivadinov, Robert

AU - Sicotte, Nancy L.

AU - Pelletier, Daniel

AU - Reich, Daniel S.

PY - 2016/11/11

Y1 - 2016/11/11

N2 - Over the past few years, MRI has become an indispensable tool for diagnosing multiple sclerosis (MS). However, the current MRI criteria for MS diagnosis have imperfect sensitivity and specificity. The central vein sign (CVS) has recently been proposed as a novel MRI biomarker to improve the accuracy and speed of MS diagnosis. Evidence indicates that the presence of the CVS in individual lesions can accurately differentiate MS from other diseases that mimic this condition. However, the predictive value of the CVS for the development of clinical MS in patients with suspected demyelinating disease is still unknown. Moreover, the lack of standardization for the definition and imaging of the CVS currently limits its clinical implementation and validation. On the basis of a thorough review of the existing literature on the CVS and the consensus opinion of the members of the North American Imaging in Multiple Sclerosis (NAIMS) Cooperative, this article provides statements and recommendations aimed at helping radiologists and neurologists to better understand, refine, standardize and evaluate the CVS in the diagnosis of MS.

AB - Over the past few years, MRI has become an indispensable tool for diagnosing multiple sclerosis (MS). However, the current MRI criteria for MS diagnosis have imperfect sensitivity and specificity. The central vein sign (CVS) has recently been proposed as a novel MRI biomarker to improve the accuracy and speed of MS diagnosis. Evidence indicates that the presence of the CVS in individual lesions can accurately differentiate MS from other diseases that mimic this condition. However, the predictive value of the CVS for the development of clinical MS in patients with suspected demyelinating disease is still unknown. Moreover, the lack of standardization for the definition and imaging of the CVS currently limits its clinical implementation and validation. On the basis of a thorough review of the existing literature on the CVS and the consensus opinion of the members of the North American Imaging in Multiple Sclerosis (NAIMS) Cooperative, this article provides statements and recommendations aimed at helping radiologists and neurologists to better understand, refine, standardize and evaluate the CVS in the diagnosis of MS.

UR - http://www.scopus.com/inward/record.url?scp=84994718072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994718072&partnerID=8YFLogxK

U2 - 10.1038/nrneurol.2016.166

DO - 10.1038/nrneurol.2016.166

M3 - Article

JO - Nature Reviews Neurology

JF - Nature Reviews Neurology

SN - 1759-4758

ER -